Hideyuki Dei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hideyuki Dei has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Katsuhiko Uesaka
Division of Hepato‐Biliary‐Pancreatic Surgery Shizuoka Cancer Center Shizuoka Japan
2 shared publications - Shimpei Otsuka
Division of Hepato‐Biliary‐Pancreatic Surgery Shizuoka Cancer Center Shizuoka Japan
2 shared publications - Hirotoshi Noda
Department of Surgery, Yokkaichi Municipal Hospital, Yokkaichi, Japan
1 shared publication Katsuhisa Ohgi
1 shared publication- Katsuhisa Ohgi
Division of Hepato‐Biliary‐Pancreatic Surgery Shizuoka Cancer Center Shizuoka Japan
1 shared publication - Kazuo Hara
Department of Gastroenterology, Aichi Cancer Center, Nagoya, Japan
1 shared publication
Latest Publications
- 13 August 2026
- Published by Wiley in Hepatology Research
Des‐Gamma‐Carboxy Prothrombin Is Associated With Tumor Aggressiveness and Recurrence in Resected Early‐Stage Hepatocellular Carcinoma: A Clinicopathological and Molecular Analysis
Aim: Alpha‐fetoprotein (AFP) and des‐gamma‐carboxy prothrombin (DCP) are widely used tumor markers for hepatocellular carcinoma (HCC); however, their relative prognostic significance in early‐stage disease remains unclear. This study aimed to compare the prognostic impact of AFP and DCP in resected HCC and to explore their underlying molecular characteristics. Methods: We retrospectively analyzed 482 patients who underwent curative resection for HCC. Patients were classified into four groups according to AFP and DCP levels: Negative, AFP‐only, DCP‐only, and Dual‐positive. Recurrence‐free survival (RFS) and prognostic factors were evaluated. In a subset of 204 patients, gene expression profiling was conducted to investigate molecular differences. Results: Among BCLC stage 0/A patients ( n = 406), RFS was stratified according to tumor marker status. The DCP‐only group showed significantly worse RFS than the AFP‐only group (5‐year RFS: 39.5% vs. 52.7%, p = 0.026) and was characterized by larger tumor size (median, 39 vs. 18 mm, p < 0.001) and more frequent portal venous invasion (29% vs. 14%, p = 0.052). Multivariable analysis identified elevated DCP as an independent prognostic factor (hazard ratio 1.48, p = 0.004). In contrast, among stage B/C patients ( n = 76), survival outcomes were uniformly poor and not stratified by tumor marker. Gene expression analysis revealed the upregulation of SFN and downregulation of DCN in DCP‐elevated tumors, suggesting extracellular matrix destabilization that may contribute to tumor aggressiveness. Conclusions: Elevated DCP reflects aggressive tumor biology and identifies patients at high risk of recurrence after resection for BCLC stage 0/A HCC. These findings support the clinical utility of DCP for risk stratification and postoperative surveillance for early‐stage HCC.
- 13 August 2026
- Published by Wiley in Hepatology Research
Des‐Gamma‐Carboxy Prothrombin Is Associated With Tumor Aggressiveness and Recurrence in Resected Early‐Stage Hepatocellular Carcinoma: A Clinicopathological and Molecular Analysis
Aim: Alpha‐fetoprotein (AFP) and des‐gamma‐carboxy prothrombin (DCP) are widely used tumor markers for hepatocellular carcinoma (HCC); however, their relative prognostic significance in early‐stage disease remains unclear. This study aimed to compare the prognostic impact of AFP and DCP in resected HCC and to explore their underlying molecular characteristics. Methods: We retrospectively analyzed 482 patients who underwent curative resection for HCC. Patients were classified into four groups according to AFP and DCP levels: Negative, AFP‐only, DCP‐only, and Dual‐positive. Recurrence‐free survival (RFS) and prognostic factors were evaluated. In a subset of 204 patients, gene expression profiling was conducted to investigate molecular differences. Results: Among BCLC stage 0/A patients ( n = 406), RFS was stratified according to tumor marker status. The DCP‐only group showed significantly worse RFS than the AFP‐only group (5‐year RFS: 39.5% vs. 52.7%, p = 0.026) and was characterized by larger tumor size (median, 39 vs. 18 mm, p < 0.001) and more frequent portal venous invasion (29% vs. 14%, p = 0.052). Multivariable analysis identified elevated DCP as an independent prognostic factor (hazard ratio 1.48, p = 0.004). In contrast, among stage B/C patients ( n = 76), survival outcomes were uniformly poor and not stratified by tumor marker. Gene expression analysis revealed the upregulation of SFN and downregulation of DCN in DCP‐elevated tumors, suggesting extracellular matrix destabilization that may contribute to tumor aggressiveness. Conclusions: Elevated DCP reflects aggressive tumor biology and identifies patients at high risk of recurrence after resection for BCLC stage 0/A HCC. These findings support the clinical utility of DCP for risk stratification and postoperative surveillance for early‐stage HCC.
- Open Access
- 6 December 2025
- Published by Elsevier in Clinical Surgical Oncology
- Vol. 4 (4)
Reappraising the prognostic role of liver resection as part of extended cholecystectomy for T2 gallbladder cancer
- 6 December 2025
- Published by Elsevier in Clinical Surgical Oncology
- Vol. 4 (4)
Open AccessReappraising the prognostic role of liver resection as part of extended cholecystectomy for T2 gallbladder cancer